Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents HealthCap and Wilson Therapeutics AB in private placement
Mandate

Vinge represents HealthCap and Wilson Therapeutics AB in private placement

May 22, 2014

Wilson Therapeutics AB has completed a private placement of USD 40,000,000 (SEK 260,000,000) directed to the venture capital firms Abingworth LLP and MVM Life Science Partners LLP and the existing investor HealthCap.

Wilson Therapeutics AB is a life science company focused on the development of drugs for the treatment of Wilson’s Disease, a rare genetic disease that affects approximately 1 in 15,000 people worldwide. The private placement is conducted to finance further product development, clinical trials and commercialisation of the company’s products.

Vinge represented HealthCap and Wilson Therapeutics AB in the private placement and Vinge’s team consisted of partner Jesper Ottergren together with, among others, Kristian Ford and Karin Engström.

Related

Vinge advises Platzer on a combined asset swap transaction with the Port of Gothenburg concerning properties in Arendal

 Vinge has advised Platzer on a combined asset swap transaction with the Port of Gothenburg comprising the sale of the property Arendal 1:28, parts of the properties Arendal 1:29 and Arendal 1:31, and the acquisition of part of the property Arendal 764:291.
April 08, 2026

Vinge has advised SEB, Swedbank and Danske Bank in connection with a bridge facility to Catena

 Vinge has advised Skandinaviska Enskilda Banken AB (publ), Swedbank AB (publ) and Danske Bank A/S in their capacities as mandated lead arrangers and bookrunners in connection with a term loan bridge facility in an aggregate amount of SEK 4,360,000,000, EUR 195,000,000 and DKK 170,000,000 to Catena AB (publ).
April 02, 2026

Vinge advises the founders of Nordic Knots in connection with the investment in the company by Imaginary Ventures and other investors

Vinge has advised the founders of Nordic Knots in connection with an investment in the company led by Imaginary Ventures, with additional investors including Creades, IRIS Ventures and St Dominique Capital.
April 02, 2026